Close Menu

NEW YORK – Exact Sciences reported after the close of the market on Tuesday that its fourth quarter revenues rose 107 percent year over year, thanks to a 63 percent increase in testing volumes for its Cologuard colorectal cancer screening test.

For the three months ended Dec. 31, 2019, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $295.6 million, up from $143.0 million a year earlier, and beating the average Wall Street estimate of $283.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.